Orvis® Broncho Thyme (Syrup) Instructions for Use
Marketing Authorization Holder
Evalar, CJSC (Russia)
Contact Information
Evalar, CJSC (Russia)
ATC Code
R05CA (Expectorants)
Active Substance
Thyme (Ph.Eur. European Pharmacopoeia)
Dosage Form
| Orvis® Broncho Thyme | Syrup: bottle 100 ml |
Dosage Form, Packaging, and Composition
Syrup as a brown liquid with a characteristic odor.
| 100 g | |
| Thyme herb liquid extract* | 9 g |
| Containing thymol 0.028% | |
* Thyme herb liquid extract is obtained from Thyme herb (Thymus vulgaris L., fam. Lamiaceae). The ratio of herbal drug substance to extract is 1:2-2.5.
Extraction solvents: Ammonia 25% solution, glycerol 100%, ethanol 95%, purified water – in a ratio of 1:42.5:162.5:294.
Excipients: potassium sorbate, citric acid monohydrate, caramel color, glycerol (glycerin), liquid sorbitol (non-crystallizing), purified water.
100 ml – dark glass bottles (1) – cardboard packs.
A measuring cup may be included in the cardboard pack.
Clinical-Pharmacological Group
Herbal preparation with expectorant effect
Pharmacotherapeutic Group
Drugs used for cough and colds; expectorants, excluding combinations with antitussives; expectorants
Pharmacological Action
The drug has an expectorant effect, thins sputum and reduces its viscosity. The active substances of the drug – thymol and carvacrol – also have an antimicrobial effect.
Pharmacokinetics
The action of the drug is the result of the combined action of the active substances of Thyme herb extract, therefore conducting pharmacokinetic studies is not possible; all components together cannot be tracked using markers or bioassays.
Indications
For adults and children aged 1 year and older
- In the complex therapy of infectious and inflammatory diseases of the respiratory tract, accompanied by cough with difficult-to-discharge sputum (including bronchitis, tracheitis, tracheobronchitis, whooping cough).
ICD codes
| ICD-10 code | Indication |
| J06.9 | Acute upper respiratory infection, unspecified |
| J22 | Acute lower respiratory infection, unspecified |
| R05 | Cough |
| R09.3 | Sputum |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Orally, regardless of meals. The syrup can be taken undiluted or diluted with water.
Adults
2-3 teaspoons (10-15 ml) of syrup 3-4 times/day. The duration of use of the drug is determined by therapeutic necessity and the duration of the disease.
Children
The dosage regimen for children over 12 years does not differ from the dosage regimen for adults.
At the age of 5 to 12 years – 1-2 teaspoons (5-10 ml) of syrup 3-4 times/day.
At the age of 1 to 5 years – 1 teaspoon (5 ml) of syrup 2-3 times/day.
The safety of the drug Orvis® Broncho Thyme in children from 0 to 1 year has not been established. Data are not available.
Adverse Reactions
Possible occurrence of allergic reactions.
Due to the sorbitol content, irritation of the gastric mucosa and diarrhea may occur when taking the drug.
If side effects not described in this instruction occur, the patient should discontinue the drug and inform the attending physician.
Contraindications
- Hypersensitivity to Thyme herb extract or to any of the excipients included in the drug;
- Cardiac decompensation;
- Gastritis;
- Peptic ulcer of the stomach and duodenum in the acute phase;
- Hereditary fructose intolerance; sucrase/isomaltase deficiency; glucose-galactose malabsorption;
- Children under 1 year of age.
With caution
- Liver diseases;
- Alcoholism;
- Traumatic brain injury;
- Brain diseases;
- Children aged 1 year and older.
Use in Pregnancy and Lactation
Pregnancy
The drug Orvis® Broncho Thyme is not recommended for use during pregnancy (due to the lack of sufficient clinical experience in this category of patients).
Breastfeeding period
The drug Orvis® Broncho Thyme is not recommended for use during breastfeeding (due to the lack of sufficient clinical experience in this category of patients).
Fertility
Data are not available.
Use in Hepatic Impairment
Use with caution in liver diseases.
Pediatric Use
Contraindicated for use in children under 1 year of age.
Special Precautions
Due to the ethanol content, children under 12 years of age should take the drug on the recommendation and under the supervision of a physician. The ethyl alcohol content in the drug is not more than 4%.
One teaspoon of the drug (5 ml) contains not more than 0.16 g of absolute ethyl alcohol (i.e., anhydrous ethyl alcohol).
For children from 1 to 5 years, the maximum single dose contains not more than 0.16 g of absolute ethyl alcohol, the maximum daily dose contains not more than 0.48 g of absolute ethyl alcohol.
For children from 5 to 12 years, the maximum single dose contains not more than 0.32 g of absolute ethyl alcohol, the maximum daily dose contains not more than 1.28 g of absolute ethyl alcohol;
For adults and children over 12 years, the maximum single dose contains not more than 0.48 g of absolute ethyl alcohol, the maximum daily dose contains not more than 1.92 g of absolute ethyl alcohol.
Excipients
The drug Orvis® Broncho Thyme contains sorbitol. Patients with rare hereditary fructose intolerance should not take this drug.
100 g of the drug contains 31.5 g of sorbitol (calculated as anhydrous sorbitol).
1 teaspoon of syrup (5 ml) contains 1.85 g of sorbitol, which corresponds to 0.15 XE.
Effect on ability to drive vehicles and mechanisms
When using the drug Orvis® Broncho Thyme, caution should be exercised when engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions (driving a car and other vehicles, working with moving mechanisms, work of a dispatcher and operator).
Overdose
Symptoms: possible irritation of the gastrointestinal mucosa, vomiting, diarrhea.
Treatment: symptomatic.
Drug Interactions
The drug should not be used simultaneously with drugs containing codeine and other antitussive drugs, as this makes it difficult to cough up liquefied sputum.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C (77°F). Shelf life – 3 years. Do not use after the expiration date.
After opening the bottle, the drug is suitable for use within 1 year.
Dispensing Status
The drug is available without a prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer